🔗 Share this article

As the US undertakes historic adjustments to its vaccine recommendations, a particular individual has emerged in a surprising turn: Dr. Tracy Beth Høeg, a Danish American sports physician and public health researcher who first made her name by questioning Covid vaccines throughout the pandemic and has focused upon potential fatalities following Covid immunization in her recent tenure at the US Food and Drug Administration (FDA).

Scheduled Shifts to Pediatric Vaccine Schedule

Public health authorities had intended to unveil sweeping changes to the pediatric vaccine schedule recently, synchronizing the US with the Danish national calendar, according to reports – a substantial departure that would put the US out of step with many the international standard with little proof for benefit. The announcement has been postponed until the new year.

Instead of the top vaccines chief, Tracy Beth Høeg is listed to speak at the event. She was just designated acting director of the FDA’s drug evaluation center, the fifth appointee to head the division this calendar year.

A Shift at the Agency

The acting appointment may indicate a tighter collaboration between the pharmaceutical and vaccine centers as Høeg and Prasad strengthen their influence at the agency – and it points to a renewed priority upon rolling back previously authorized immunizations at the FDA.

Høeg has often pushed for ending specific childhood immunization guidelines in the US to become more in line with Denmark's approach, a country with universal health coverage and a number of inhabitants approximately the size of Wisconsin’s.

So far statements, she has continued to focus on vaccination policy – traditionally the domain of Prasad, chief of the FDA’s vaccine center – as opposed to drug regulation.

Concerns Over Background

The appointee has no apparent track record in pharmaceutical research, oversight or leadership, which has been customary for previous directors of the biologics center. She has worked at the FDA as a top consultant to the commissioner and CBER since earlier this year.

“She appears not to have the requisite experience” for leading the drug-regulation department, said Jonathan Howard. “She’s never run a scientific study. She lacks experience in leading a major agency. She lacks background in drug approvals.”

Former commissioners of the center would “be deeply familiar with regulatory frameworks and the science of medication creation”, noted a former acting FDA commissioner. “Frankly, she lacks the kind of background that former directors who headed CBER have had.”

This division has an vast portfolio at the FDA, Woodcock stated.

“Everybody just pays attention on the new drug program, but the generic drug division clears a multitude of off-brand pharmaceuticals. There’s a biosimilars program, non-prescription drug unit and more, and each of these need to be managed,” Woodcock noted. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a major leadership component to the role, which supervises more than 5,000 personnel. “It’s a enormous management job, if you do it right,” Woodcock said.

Agency Reaction and Controversial Policies

When asked about inquiries about Dr. Høeg's qualifications and whether this assignment represents more teamwork among FDA leaders on vaccines, a spokesperson said that the “questions rely on incorrect assumptions”.

“Her experience aligns with the duties of her position,” the spokesperson explained, citing the time Dr. Høeg spent counseling the FDA commissioner on “drug safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Høeg inherits the commissioner’s controversial priority voucher program, a disputed expedited therapy clearance system that apparently concerned her predecessors. “How are these drugs being picked for this voucher program? Who makes the decisions?” Howard questioned. “There’s a lot of confidentiality going on at the agency right now.”

In general, he remarked, “the agency looks to be trending towards more relaxed regulations of most medications, except for immunizations.”

Documented Past Work on Vaccines

Regarding immunizations, Dr. Høeg has a more documented, if concerning, track record, Howard observe. She authored a study using unverified public submissions to assess the incidence of heart inflammation following COVID-19 immunization. She advised the Florida chief medical officer Joseph Ladapo, who allegedly have altered data to indicate COVID-19 vaccinations are riskier than they are.

Included in her “desired changes” for the current administration encompassed revising regulations for recently developed shots and discontinuing “unnecessary” immunizations, she remarked following the vote on a podcast. At the agency, Dr. Høeg has reportedly floated the idea of preventing young men from receiving COVID-19 vaccinations.

“She is an all-around ideologue who begins with her preconceived notions and works backwards to retrofit the data in a extremely misleading, fraudulent fashion,” Dr. Howard said.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg aligned with other skeptics, {like|